Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) T Cell Antigen Gp39 Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global T Cell Antigen Gp39 Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 ECI-006
      • 1.3.3 Hepatitis B vaccine
      • 1.3.4 INX-021
      • 1.3.5 ISF-35
      • 1.3.6 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global T Cell Antigen Gp39 Market Share by Application (2019-2025)
      • 1.4.2 Graft Versus Host Disease
      • 1.4.3 Breast Cancer
      • 1.4.4 Bladder Cancer
      • 1.4.5 Panceratic Cancer
      • 1.4.6 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global T Cell Antigen Gp39 Market Size
      • 2.1.1 Global T Cell Antigen Gp39 Revenue 2014-2025
      • 2.1.2 Global T Cell Antigen Gp39 Sales 2014-2025
    • 2.2 T Cell Antigen Gp39 Growth Rate by Regions
      • 2.2.1 Global T Cell Antigen Gp39 Sales by Regions 2014-2019
      • 2.2.2 Global T Cell Antigen Gp39 Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 T Cell Antigen Gp39 Sales by Manufacturers
      • 3.1.1 T Cell Antigen Gp39 Sales by Manufacturers 2014-2019
      • 3.1.2 T Cell Antigen Gp39 Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 T Cell Antigen Gp39 Revenue by Manufacturers (2014-2019)
      • 3.2.2 T Cell Antigen Gp39 Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global T Cell Antigen Gp39 Market Concentration Ratio (CR5 and HHI)
    • 3.3 T Cell Antigen Gp39 Price by Manufacturers
    • 3.4 Key Manufacturers T Cell Antigen Gp39 Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into T Cell Antigen Gp39 Market
    • 3.6 Key Manufacturers T Cell Antigen Gp39 Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 ECI-006 Sales and Revenue (2014-2019)
      • 4.1.2 Hepatitis B vaccine Sales and Revenue (2014-2019)
      • 4.1.3 INX-021 Sales and Revenue (2014-2019)
      • 4.1.4 ISF-35 Sales and Revenue (2014-2019)
      • 4.1.5 Others Sales and Revenue (2014-2019)
    • 4.2 Global T Cell Antigen Gp39 Sales Market Share by Type
    • 4.3 Global T Cell Antigen Gp39 Revenue Market Share by Type
    • 4.4 T Cell Antigen Gp39 Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global T Cell Antigen Gp39 Sales by Application

    6 United States

    • 6.1 United States T Cell Antigen Gp39 Breakdown Data by Company
    • 6.2 United States T Cell Antigen Gp39 Breakdown Data by Type
    • 6.3 United States T Cell Antigen Gp39 Breakdown Data by Application

    7 European Union

    • 7.1 European Union T Cell Antigen Gp39 Breakdown Data by Company
    • 7.2 European Union T Cell Antigen Gp39 Breakdown Data by Type
    • 7.3 European Union T Cell Antigen Gp39 Breakdown Data by Application

    8 China

    • 8.1 China T Cell Antigen Gp39 Breakdown Data by Company
    • 8.2 China T Cell Antigen Gp39 Breakdown Data by Type
    • 8.3 China T Cell Antigen Gp39 Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World T Cell Antigen Gp39 Breakdown Data by Company
    • 9.2 Rest of World T Cell Antigen Gp39 Breakdown Data by Type
    • 9.3 Rest of World T Cell Antigen Gp39 Breakdown Data by Application
    • 9.4 Rest of World T Cell Antigen Gp39 Breakdown Data by Countries
      • 9.4.1 Rest of World T Cell Antigen Gp39 Sales by Countries
      • 9.4.2 Rest of World T Cell Antigen Gp39 Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Biogen, Inc.
      • 10.1.1 Biogen, Inc. Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of T Cell Antigen Gp39
      • 10.1.4 T Cell Antigen Gp39 Product Introduction
      • 10.1.5 Biogen, Inc. Recent Development
    • 10.2 Bristol-Myers Squibb Company
      • 10.2.1 Bristol-Myers Squibb Company Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of T Cell Antigen Gp39
      • 10.2.4 T Cell Antigen Gp39 Product Introduction
      • 10.2.5 Bristol-Myers Squibb Company Recent Development
    • 10.3 eTheRNA Immunotherapies NV
      • 10.3.1 eTheRNA Immunotherapies NV Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of T Cell Antigen Gp39
      • 10.3.4 T Cell Antigen Gp39 Product Introduction
      • 10.3.5 eTheRNA Immunotherapies NV Recent Development
    • 10.4 ImmuNext, Inc.
      • 10.4.1 ImmuNext, Inc. Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of T Cell Antigen Gp39
      • 10.4.4 T Cell Antigen Gp39 Product Introduction
      • 10.4.5 ImmuNext, Inc. Recent Development
    • 10.5 Juno Therapeutics Inc.
      • 10.5.1 Juno Therapeutics Inc. Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of T Cell Antigen Gp39
      • 10.5.4 T Cell Antigen Gp39 Product Introduction
      • 10.5.5 Juno Therapeutics Inc. Recent Development
    • 10.6 MedImmune, LLC
      • 10.6.1 MedImmune, LLC Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of T Cell Antigen Gp39
      • 10.6.4 T Cell Antigen Gp39 Product Introduction
      • 10.6.5 MedImmune, LLC Recent Development
    • 10.7 Targovax AS
      • 10.7.1 Targovax AS Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of T Cell Antigen Gp39
      • 10.7.4 T Cell Antigen Gp39 Product Introduction
      • 10.7.5 Targovax AS Recent Development
    • 10.8 XL-protein GmbH
      • 10.8.1 XL-protein GmbH Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of T Cell Antigen Gp39
      • 10.8.4 T Cell Antigen Gp39 Product Introduction
      • 10.8.5 XL-protein GmbH Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 T Cell Antigen Gp39 Sales Channels
      • 11.2.2 T Cell Antigen Gp39 Distributors
    • 11.3 T Cell Antigen Gp39 Customers

    12 Market Forecast

    • 12.1 Global T Cell Antigen Gp39 Sales and Revenue Forecast 2019-2025
    • 12.2 Global T Cell Antigen Gp39 Sales Forecast by Type
    • 12.3 Global T Cell Antigen Gp39 Sales Forecast by Application
    • 12.4 T Cell Antigen Gp39 Forecast by Regions
      • 12.4.1 Global T Cell Antigen Gp39 Sales Forecast by Regions 2019-2025
      • 12.4.2 Global T Cell Antigen Gp39 Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of T Cell Antigen Gp39 is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for T Cell Antigen Gp39.

      This report studies the global market size of T Cell Antigen Gp39, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the T Cell Antigen Gp39 sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Biogen, Inc.
      Bristol-Myers Squibb Company
      eTheRNA Immunotherapies NV
      ImmuNext, Inc.
      Juno Therapeutics Inc.
      MedImmune, LLC
      Targovax AS
      XL-protein GmbH

      Market Segment by Product Type
      ECI-006
      Hepatitis B vaccine
      INX-021
      ISF-35
      Others

      Market Segment by Application
      Graft Versus Host Disease
      Breast Cancer
      Bladder Cancer
      Panceratic Cancer
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the T Cell Antigen Gp39 status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key T Cell Antigen Gp39 manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of T Cell Antigen Gp39 are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now